<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUeP J4Z _tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff= 20231103021054&amp;fc=20230708114047<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;ff=20231103021054&amp;fc=20230708114047" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 11 月 3 日星期五 06:10:57 +0000</lastbuilddate><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>跨大脑区域和细胞类型的突触多样性的蛋白质组景观</title><link/>https://pubmed.ncbi.nlm.nih.gov/37918396/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>神经元使用不同的蛋白质组合建立突触接触，这些蛋白质组合定义了突触的特异性、功能和可塑性潜力；然而，突触蛋白质组的多样性在很大程度上仍未被探索。我们从 7 个不同的转基因小鼠品系中制备了突触体，并带有荧光标记的突触前末端。通过荧光激活突触体分选（FASS），我们分离并分析了 5 个不同的大脑区域的 18 个不同的蛋白质组... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 10 月 26 日：S0092-8674(23)01082-6. doi: 10.1016/j.cell.2023.09.028. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">神经元使用不同的蛋白质组合建立突触接触，这些蛋白质组合定义了突触的特异性、功能和可塑性潜力；然而，突触蛋白质组的多样性在很大程度上仍未被探索。我们从 7 个不同的转基因小鼠品系中制备了突触体，并带有荧光标记的突触前末端。我们利用荧光激活突触体分选（FASS）对 5 个不同的大脑区域进行分离和分析 18 种不同突触类型的蛋白质组。我们发现了约 1,800 个独特的突触类型富集蛋白质，并将数千种蛋白质分配给不同类型的突触（https： //syndive.org/）。我们识别了共享的突触蛋白模块，并强调了突触特化的蛋白质组热点。我们揭示了纹状体多巴胺能蛋白质组的独特和共同特征，并发现了与不同中间神经元类别的功能特性相关的蛋白质组特征。这项研究提供了突触的分子系统生物学分析，以及将感兴趣的突触亚型的蛋白质组信息与细胞或电路水平实验相整合的框架。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37918396/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37918396</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.09.028>10.1016/j.cell.2023.09.028</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37918396</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator>马克·范·奥斯特鲁姆</dc:creator><dc:creator>托马斯·M·布洛克</dc:creator><dc:creator>斯特凡诺·詹多梅尼科</dc:creator><dc:creator>苏珊·汤姆·迪克</dc:creator><dc:creator>格奥尔基·图舍夫</dc:creator><dc:creator>妮可·菲尔斯特</dc:creator><dc:creator>朱利安·D·兰格</dc:creator><dc:creator>艾琳·M·舒曼</dc:creator><dc:date>2023-11-02</dc:date><dc:source>细胞</dc:source><dc:title>跨大脑区域和细胞类型的突触多样性的蛋白质组景观</dc:title><dc:identifier>下午:37918396</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.028</dc:identifier></item><item><title>发现针对铜绿假单胞菌的高度中和人类抗体</title><link/>https://pubmed.ncbi.nlm.nih.gov/37918395/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>耐药铜绿假单胞菌 (PA) 对人类健康构成了新的威胁，迫切需要替代治疗方法。在这里，我们破译了一组患者中 B 细胞和抗体对毒力相关 III 型分泌系统 (T3SS) 的反应单细胞分析揭示了针对 T3SS 针尖蛋白 PcrV 的多种 B 细胞受体库，从而能够产生单克隆抗体 (mAb)，从而消除... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 10 月 27 日：S0092-8674(23)01084-X. doi: 10.1016/j.cell.2023.10.002. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">耐药铜绿假单胞菌 (PA) 对人类健康构成了新的威胁，迫切需要替代治疗方法。在这里，我们破译了一组患者中 B 细胞和抗体对毒力相关 III 型分泌系统 (T3SS) 的反应单细胞分析揭示了针对 T3SS 针尖蛋白 PcrV 的多种 B 细胞受体库，从而能够产生单克隆抗体 (mAb)，消除 T3SS 介导的细胞毒性。涉及冷冻电子显微镜的机制研究发现了一种表面-暴露的 C 末端 PcrV 表位作为中性高度化单克隆抗体的靶标，对耐药 PA 分离株具有广泛的活性。这些抗 PcrV 单克隆抗体与体内常规抗生素治疗一样有效。我们的研究表明，慢性感染患者是一个来源中和抗体，可用作针对 PA 的治疗方法。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37918395/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37918395</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.10.002>10.1016/j.cell.2023.10.002</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37918395</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator>亚历山大·西蒙尼斯</dc:creator><dc:creator>克里斯托夫·克雷尔</dc:creator><dc:creator>亚历山德拉·阿不思</dc:creator><dc:creator>凯瑟琳娜·罗克斯</dc:creator><dc:creator>标元</dc:creator><dc:creator>德米特里·霍尔兹曼</dc:creator><dc:creator>乔安娜·威尔姆斯</dc:creator><dc:creator>西尔维娅·朱伯</dc:creator><dc:creator>丽莎·科特格</dc:creator><dc:creator>桑德拉·温特</dc:creator><dc:creator>梅克·迈耶</dc:creator><dc:creator>克里斯汀·施密特</dc:creator><dc:creator>亨宁·格鲁尔</dc:creator><dc:creator>塞巴斯蒂安·J·西奥博尔德</dc:creator><dc:creator>安娜·玛丽亚·赫尔曼</dc:creator><dc:creator>克里斯蒂娜·迈耶</dc:creator><dc:creator>梅里耶姆·塞达·埃尔坎奥卢</dc:creator><dc:creator>尼娜·克莱默</dc:creator><dc:creator>安杰·蒙德</dc:creator><dc:creator>迈克尔·哈勒克</dc:creator><dc:creator>格尔德·法特肯霍伊尔</dc:creator><dc:creator>曼努埃尔·科赫</dc:creator><dc:creator>哈拉尔德·塞弗特</dc:creator><dc:creator>恩斯特·里切尔</dc:creator><dc:creator>托马斯·C·马洛维茨</dc:creator><dc:creator>西尔克·范·科宁斯布鲁根-里切尔</dc:creator><dc:creator>弗洛里安·克莱因</dc:creator><dc:creator>简·雷布尼克</dc:creator><dc:date>2023-11-02</dc:date><dc:source>细胞</dc:source><dc:title>发现针对铜绿假单胞菌的高度中和人类抗体</dc:title><dc:identifier>下午:37918395</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.002</dc:identifier></item><item><title>嵌合自身抗体受体 T 细胞消耗 NMDA 受体特异性 B 细胞</title><link/>https://pubmed.ncbi.nlm.nih.gov/37918394/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>抗 NMDA 受体 (NMDAR) 自身抗体会引起 NMDAR 脑炎，这是最常见的自身免疫性脑炎，导致精神病、癫痫发作和自主神经功能障碍。目前的治疗方法包括广泛的免疫抑制或非选择性抗体去除。我们开发了 NMDAR 特异性嵌合自身抗体受体 (NMDAR) ) -CAAR) T 细胞选择性消除抗 NMDAR B 细胞和致病自身抗体。NMDAR-CAAR 由细胞外多亚基 NMDAR 自身抗原融合... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 10 月 26 日：S0092-8674(23)01083-8. doi: 10.1016/j.cell.2023.10.001. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">抗 NMDA 受体 (NMDAR) 自身抗体会引起 NMDAR 脑炎，这是最常见的自身免疫性脑炎，导致精神病、癫痫发作和自主神经功能障碍。目前的治疗方法包括广泛的免疫抑制或非选择性抗体去除。我们开发了 NMDAR 特异性嵌合自身抗体受体 (NMDAR) ) -CAAR) T 细胞选择性消除抗 NMDAR B 细胞和致病自身抗体。NMDAR-CAAR 由细胞外多亚基 NMDAR 自身抗原与细胞内 4-1BB/CD3ze 结构域融合组成。NMDAR-CAAR T 细胞识别大即使在高浓度自身抗体存在的情况下，NMDAR-CAAR T 细胞也能释放效应分子、增殖并选择性杀死抗原特异性靶细胞系。在被动转移小鼠模型中，NMDAR-CAAR T 细胞导致抗- NMDAR B细胞系和持续降低自身抗体水平，且没有显着靶标毒性。对患者的治疗可以减少副作用，预防复发，改善长期预后。我们的临床前工作为CAAR T细胞I/II期铺平了道路NMDAR 脑炎和其他自身抗体介导的疾病的试验。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37918394/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37918394</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.10.001>10.1016/j.cell.2023.10.001</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37918394</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator>莫森·赖因克</dc:creator><dc:creator>尼尔斯·冯·瓦尔登堡</dc:creator><dc:creator>玛丽·霍梅尔</dc:creator><dc:creator>汉斯·克里斯蒂安·科尔瑙</dc:creator><dc:creator>格雷戈里奥·斯帕尼</dc:creator><dc:creator>李露西</dc:creator><dc:creator>雅各布·克雷伊</dc:creator><dc:creator>埃莉萨·桑切斯-森丁</dc:creator><dc:creator>索尼娅·布卢梅瑙</dc:creator><dc:creator>多米尼克·斯塔珀特</dc:creator><dc:creator>海伦娜拉德布鲁赫</dc:creator><dc:creator>安雅·E·豪瑟</dc:creator><dc:creator>安妮特·昆克勒</dc:creator><dc:creator>伊南·埃德斯</dc:creator><dc:creator>迪特玛·施密茨</dc:creator><dc:creator>哈拉尔德·普吕斯</dc:creator><dc:date>2023-11-02</dc:date><dc:source>细胞</dc:source><dc:title>嵌合自身抗体受体 T 细胞消耗 NMDA 受体特异性 B 细胞</dc:title><dc:identifier>下午:37918394</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.001</dc:identifier></item><item><title>预防心房颤动：行动呼吁</title><link/>https://pubmed.ncbi.nlm.nih.gov/37919240/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 31 日：ehad738。doi：10.1093/eurheartj/ehad738。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37919240/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37919240</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad738>10.1093/eurheartj/ehad738</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37919240</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator>阿德里安·D·埃利奥特</dc:creator><dc:creator>埃米莉亚·J·本杰明</dc:creator><dc:creator>梅丽莎·E·米德尔多普</dc:creator><dc:date>2023-11-02</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>预防心房颤动：行动呼吁</dc:title><dc:identifier>下午：37919240</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad738</dc:identifier></item><item><title> 2023年世界心脏联合会风湿性心脏病超声心动图诊断指南</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914787/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>风湿性心脏病 (RHD) 是导致低收入和中等收入国家儿童和年轻人以及高收入国家某些高危人群发病和死亡的重要且可预防的原因。2012 年世界心脏联盟超声心动图标准为识别 RHD 提供了标准化方法，并促进了早期病例检测的改进。2012 年标准用于定义众多... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Nat Rev Cardiol。2023 年 11 月 2 日。doi：10.1038/s41569-023-00940-9。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">风湿性心脏病 (RHD) 是导致低收入和中等收入国家儿童和年轻人以及高收入国家某些高危人群发病和死亡的重要且可预防的原因。2012 年世界心脏联盟超声心动图标准为 RHD 的识别提供了标准化方法，并促进了早期病例检测的改进。2012 年的标准用于定义众多流行病学研究中的疾病负担，但研究人员和先驱者此后强调了其局限性，并促使其进行修订。在该指南的更新版本中，我们纳入了范围界定审查、专家小组和最终用户反馈中的证据，并提出了一种主动发现 RHD 病例的方法，包括使用筛选和确认标准。这些指南还引入了新的方法基于阶段的 RHD 分类，以确定疾病进展的风险。它们描述了基于人群的超声心动图主动病例发现和风险分层的最新证据和建议。还讨论了 RHD 主动病例发现的二级抗生素预防、超声心动图设备和任务共享世界心脏联合会 2023 为 RHD 流行地区的临床和研究应用提供了简明且更新的资源指南。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914787/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914787</a> | DOI： <a href=https://doi.org/10.1038/s41569-023-00940-9>10.1038/s41569-023-00940-9</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914787</guid><pubDate> Thu, 02 Nov 2023 06:00:00 -0400</pubDate><dc:creator>乔斯林·鲁韦贝贝拉</dc:creator><dc:creator>詹姆斯·马兰古</dc:creator><dc:creator>朱利叶斯·查查·姆维塔</dc:creator><dc:creator>安娜·奥尔加·莫昆比</dc:creator><dc:creator>克莱奥尼斯·莫塔</dc:creator><dc:creator>艾美·奥凯洛</dc:creator><dc:creator>布鲁诺·纳西门托</dc:creator><dc:creator>琳·索鲁普</dc:creator><dc:creator>安德里亚·比顿</dc:creator><dc:creator>约瑟夫·卡多</dc:creator><dc:creator>亚历山大·凯斯纳</dc:creator><dc:creator>拉曼·克里希纳·库马尔</dc:creator><dc:creator>约翰·劳伦森</dc:creator><dc:creator>埃洛伊·马里琼</dc:creator><dc:creator>玛丽安娜·米拉贝尔</dc:creator><dc:creator>玛丽亚·卡尔莫·佩雷拉·努内斯</dc:creator><dc:creator>丹尼尔·皮内罗</dc:creator><dc:creator>福斯托·平托</dc:creator><dc:creator>凯特·罗尔斯顿</dc:creator><dc:creator>克雷格·塞布尔</dc:creator><dc:creator>艾米桑亚胡姆比</dc:creator><dc:creator>安妮塔·萨克塞纳</dc:creator><dc:creator>凯伦·斯利瓦</dc:creator><dc:creator>安德鲁·斯蒂尔</dc:creator><dc:creator>萨图派提亚·维亚利</dc:creator><dc:creator>加文·惠顿</dc:creator><dc:creator>奈杰尔·威尔逊</dc:creator><dc:creator>莉丝尔·祖尔克</dc:creator><dc:creator>博·雷梅尼</dc:creator><dc:date>2023-11-02</dc:date><dc:source> 《自然》评论、心脏病学</dc:source><dc:title>2023年世界心脏联合会风湿性心脏病超声心动图诊断指南</dc:title><dc:identifier>下午：37914787</dc:identifier><dc:identifier> doi:10.1038/s41569-023-00940-9</dc:identifier></item><item><title>答复：针对心房颤动的症状关注：一种有前途的治疗方法和未来研究的途径</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914521/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):e183-e184.doi:10.1016/j.jacc.2023.08.047。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914521/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914521</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.047>10.1016/j.jacc.2023.08.047</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914521</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>约瑟夫·萨恩霍尔姆</dc:creator><dc:creator>布扬·洛松</dc:creator><dc:creator>弗里德·布伦瑞克</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>答复：针对心房颤动的症状关注：一种有前途的治疗方法和未来研究的途径</dc:title><dc:identifier>下午:37914521</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.047</dc:identifier></item><item><title>关于 iCBT 对有症状的阵发性心房颤动患者的疗效需谨慎</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914520/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):e181.doi:10.1016/j.jacc.2023.07.035。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914520/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914520</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.035>10.1016/j.jacc.2023.07.035</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914520</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>彼得·安德森</dc:creator><dc:creator>詹姆斯·科因</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>关于 iCBT 对有症状的阵发性心房颤动患者的疗效需谨慎</dc:title><dc:identifier>下午：37914520</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.035</dc:identifier></item><item><title>患有心房颤动和心理健康症状的绝经后妇女：值得关注的群体</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914519/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):e179.doi:10.1016/j.jacc.2023.07.037。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914519/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914519</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.037>10.1016/j.jacc.2023.07.037</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914519</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>王洁仪</dc:creator><dc:creator>贾瑞婷</dc:creator><dc:creator>榆林路</dc:creator><dc:creator>于武敏</dc:creator><dc:creator>朱爱松</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>患有心房颤动和心理健康症状的绝经后妇女：值得关注的群体</dc:title><dc:identifier>下午：37914519</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.037</dc:identifier></item><item><title>超越表面：审视 iCBT 治疗心房颤动研究中的方法学偏差</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914518/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):e177.doi:10.1016/j.jacc.2023.07.036。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914518/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914518</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.07.036>10.1016/j.jacc.2023.07.036</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914518</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>阿德里安·E·德赛·博斯特罗姆</dc:creator><dc:creator>约翰·伦德伯格</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>超越表面：审视 iCBT 治疗心房颤动研究中的方法学偏差</dc:title><dc:identifier>下午：37914518</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.07.036</dc:identifier></item><item><title>心肌肌钙蛋白测定可区分急性和慢性心肌损伤</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914517/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1885-1887.doi:10.1016/j.jacc.2023.08.048。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914517/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914517</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.048>10.1016/j.jacc.2023.08.048</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914517</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>尼尔斯·索伦森</dc:creator><dc:creator>郭琳琳</dc:creator><dc:creator>保罗·M·哈勒</dc:creator><dc:creator>法纳兹·德科迪</dc:creator><dc:creator>乔纳斯·莱马赫</dc:creator><dc:creator>阿琳娜·肖克</dc:creator><dc:creator>贝图尔·托普拉克</dc:creator><dc:creator>塔尼娅·泽勒</dc:creator><dc:creator>拉斐尔·特维伦博尔德</dc:creator><dc:creator>约翰内斯·T·诺依曼</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>心肌肌钙蛋白测定可区分急性和慢性心肌损伤</dc:title><dc:identifier>下午：37914517</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.048</dc:identifier></item><item><title> SGLT2i 与心力衰竭肾功能恶化：“高肌酐血症”耐受性的另一个证明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914516/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1864-1867.doi:10.1016/j.jacc.2023.09.797。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914516/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914516</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.797>10.1016/j.jacc.2023.09.797</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914516</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>史蒂文·G·科卡</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>SGLT2i 与心力衰竭肾功能恶化：“高肌酐血症”耐受性的另一个证明</dc:title><dc:identifier>下午：37914516</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.797</dc:identifier></item><item><title>索格列净的疗效与糖化血红蛋白水平无关</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914515/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1852-1853.doi:10.1016/j.jacc.2023.09.004。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914515/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914515</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.004>10.1016/j.jacc.2023.09.004</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914515</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>格雷格·C·福纳罗</dc:creator><dc:creator>礼萨·莫赫比</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>索格列净的疗效与糖化血红蛋白水平无关</dc:title><dc:identifier>下午：37914515</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.004</dc:identifier></item><item><title> Sotagliflozin 对成人 2 型糖尿病患者的疗效与基线血红蛋白 A1c 的关系</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914514/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>结论：在患有 HF 或肾脏疾病的 2 型糖尿病患者中，无论基线 HbA1c 如何，索格列净均可减少 HF 结局。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1842-1851.doi:10.1016/j.jacc.2023.08.050。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：SCORED（索格列净对有心血管风险的 2 型糖尿病和中度肾损伤患者心血管和肾脏事件的影响）和 SOLOIST-WHF（索格列净对心力衰竭恶化后 2 型糖尿病患者心血管事件的影响） ）试验表明，sotagliflozin（一种 SGLT1 和 SGLT2 抑制剂）可改善患有心力衰竭 (HF) 或肾脏疾病的 2 型糖尿病患者的预后。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：我们评估了索格列净对不同基线糖化血红蛋白 (HbA1c) 水平的个体心力衰竭临床结果的疗效。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：我们纳入了 SCORED 和 SOLOIST-WHF 的所有成年人。主要结局是心血管死亡、心力衰竭住院和心力衰竭紧急就诊的综合结果。与安慰剂相比，索格列净的疗效通过基线 HbA1c 使用竞争风险边际评估进行评估。比例风险模型。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：我们识别了 11,744 名成年人。HbA1c ≤7.5% 的个体在 sotagliflozin 组（每 100 人年 11.2 人）经历主要结局的发生率低于安慰剂组（每 100 人年 15.5 人）（HR：0.73； 95% CI：0.57-0.93）。同样，HbA1c 为 7.6% 至 9.0% 的个体中，sotagliflozin 组（每 100 人年 7.3 人）经历主要结局的发生率低于安慰剂组（每 100 人年 9.4 人） （HR：0.77；95% CI：0.63-0.96）。这些结果在 HbA1c >; 9.0% 的个体中也一致，sotagliflozin 组的主​​要结局发生率（7.8/100 人年）低于安慰剂组组（每 100 人年 11.6 例）（HR：0.65；95% CI：0.50-0.84）。sotagliflozin 的疗效与基线 HbA1c 水平一致（交互作用 P = 0.58）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：在患有 HF 或肾脏疾病的 2 型糖尿病患者中，无论基线 HbA1c 如何，索格列净均可减少 HF 结局。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914514/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914514</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.050>10.1016/j.jacc.2023.08.050</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914514</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>拉胡尔·阿加瓦尔</dc:creator><dc:creator>迪帕克·巴特</dc:creator><dc:creator>迈克尔·萨雷克</dc:creator><dc:creator>克里斯托弗·P·坎农</dc:creator><dc:creator>达伦·K·麦奎尔</dc:creator><dc:creator>西尔维奥·因祖奇</dc:creator><dc:creator>雷纳托·D·洛佩斯</dc:creator><dc:creator>迈克尔·J·戴维斯</dc:creator><dc:creator>菲利普·班克斯</dc:creator><dc:creator>伯特伦·皮特</dc:creator><dc:creator>菲利普·加布里埃尔·施泰格</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>Sotagliflozin 对成人 2 型糖尿病患者的疗效与基线血红蛋白 A1c 的关系</dc:title><dc:identifier>下午：37914514</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.050</dc:identifier></item><item><title>稳定胸痛无创成像测试的比较准确性：重要吗？</title><link/> https://pubmed.ncbi.nlm.nih.gov/37914513/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1839-1841.doi:10.1016/j.jacc.2023.09.805。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914513/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914513</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.805>10.1016/j.jacc.2023.09.805</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914513</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>斯文·普莱因</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>稳定胸痛无创成像测试的比较准确性：重要吗？</dc:title><dc:identifier>下午：37914513</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.805</dc:identifier></item><item><title>负荷灌注心脏磁共振与 SPECT 成像检测冠状动脉疾病的比较</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914512/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>结论：与门控 SPECT 相比，使用 0.1 mmol/kg 体重钆布醇进行的血管扩张剂应激灌注 CMR 在诊断和排除显着 CAD 方面具有更高的诊断准确性。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1828-1838.doi:10.1016/j.jacc.2023.08.046。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：GadaCAD2 是 2 项国际、多中心、前瞻性 3 期临床试验之一，这些试验导致美国食品和药物管理局批准钆布醇用于评估已知或疑似冠状动脉疾病 (CAD) 成人的心肌灌注和晚期钆增强 (LGE) ）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：预先设定的次要目标是确定应力灌注心血管磁共振 (CMR) 在检测显着 CAD 和排除显着 CAD 方面是否不劣于单光子发射计算机断层扫描 (SPECT)。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：患有已知或疑似 CAD 的参与者接受研究休息和应激灌注 CMR，与使用标准临床方案进行的门控 SPECT 进行比较。对于 CMR，腺苷或热加腺松用作血管扩张剂。钆布醇的总剂量为 0.1 mmol/kg 体重参考标准是通过定量冠状动脉造影 (QCA) 定义的 70% 狭窄。冠状动脉计算机断层扫描血管造影阴性可以排除 CAD。分析按每位患者进行。CMR、SPECT 和 QCA 评估由独立的中央核心实验室读者进行盲法评估到临床信息。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：参与者主要为男性（61.4% 为男性；平均年龄 58.9 ± 10.2 岁），并从美国 (75.0%)、澳大利亚 (14.7%)、新加坡 (5.7%) 和加拿大 (4.6%) 招募。显着 CAD 的发生率为 24.5%（n = 72 of 294）。应力灌注 CMR 在特异性 (P = 0.002)、受试者工作特征曲线下面积 (P &lt; 0.001) 和准确性 (P = 0.003) 方面优于门控 SPECT。 、阳性预测值 (P &lt; 0.001) 和阴性预测值 (P = 0.041)。CMR 对 70% QCA 狭窄的敏感性不劣于也不优于门控 SPECT。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：与门控 SPECT 相比，使用 0.1 mmol/kg 体重钆布醇进行的血管扩张剂应激灌注 CMR 在诊断和排除显着 CAD 方面具有更高的诊断准确性。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914512/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914512</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.046>10.1016/j.jacc.2023.08.046</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914512</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>安德鲁·E·新井</dc:creator><dc:creator>珍妮特·舒尔茨-门格</dc:creator><dc:creator>迪潘·J·沙阿</dc:creator><dc:creator>韩尉迟</dc:creator><dc:creator>W帕特里夏·班德蒂尼</dc:creator><dc:creator>阿伦·亚伯拉罕</dc:creator><dc:creator>帕梅拉·K·伍达德</dc:creator><dc:creator>约瑟夫·B·塞尔瓦纳亚加姆</dc:creator><dc:creator>克里斯蒂安·汉密尔顿-克雷格</dc:creator><dc:creator>谭如三</dc:creator><dc:creator>詹姆斯·卡尔</dc:creator><dc:creator>林内特·张</dc:creator><dc:creator>克里斯托弗·M·克莱默</dc:creator><dc:creator>伯恩德·J·温特斯佩格</dc:creator><dc:creator>穆克什·G·哈里辛哈尼</dc:creator><dc:creator>斯科特·D·弗拉姆</dc:creator><dc:creator>马蒂亚斯·G·弗里德里希</dc:creator><dc:creator>伊戈尔·克莱姆</dc:creator><dc:creator>苏巴·V·拉曼</dc:creator><dc:creator>丹尼尔·哈弗斯托克</dc:creator><dc:creator>刘哲宇</dc:creator><dc:creator>冈瑟·布吕根沃特</dc:creator><dc:creator>玛尔塔·桑蒂乌斯特</dc:creator><dc:creator>丹尼尔·伯曼</dc:creator><dc:creator>达德利·彭内尔</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>负荷灌注心脏磁共振与 SPECT 成像检测冠状动脉疾病的比较</dc:title><dc:identifier>下午：37914512</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.046</dc:identifier></item><item><title>肾去神经术的持续奥德赛</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914511/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1824-1827.doi:10.1016/j.jacc.2023.09.795。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914511/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914511</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.09.795>10.1016/j.jacc.2023.09.795</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914511</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>曼尼什·维纳亚克</dc:creator><dc:creator>杰弗里·W·奥林</dc:creator><dc:creator>格雷格·W·斯通</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>肾去神经术的持续奥德赛</dc:title><dc:identifier>下午：37914511</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.09.795</dc:identifier></item><item><title>服用抗高血压药物的患者去肾神经术的安全性和有效性</title><link/>https://pubmed.ncbi.nlm.nih.gov/37914510/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>结论：主要分析中各组之间没有显着差异。然而，多个次要终点分析有利于 RDN 优于假手术对照。（SPYRAL HTN-ON MED 研究 [使用 Symplicity Spyral 多电极肾去神经系统进行肾去神经的全球临床研究在没有抗高血压药物的情况下高血压不受控制的患者中]；NCT02439775）。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol.2023 年 11 月 7 日；82(19):1809-1823.doi:10.1016/j.jacc.2023.08.045。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：去肾神经术（RDN）可以降低在没有抗高血压药物的情况下高血压未得到控制的患者的血压（BP）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：该试验评估了 RDN 在抗高血压药物存在下的安全性和有效性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：SPYRAL HTN-ON MED 是一项前瞻性、随机、假对照、患者和评估者盲法试验，招募了来自全球 56 个临床中心的患者。为患者开了 1 至 3 种抗高血压药物。患者被随机分配至射频 RDN 或假对照。主要疗效终点是使用贝叶斯试验设计和分析，在 6 个月时组间平均 24 小时动态收缩压的基线调整变化。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：RDN 组（n = 206；-6.5 ± 10.7 mm Hg）和假手术对照组（n = 131；-4.5 ± 10.3 mm Hg）之间平均 24 小时动态收缩压从基线到 6 个月的治疗差异）为-1.9 mm Hg（95% CI：-4.4至0.5 mm Hg；P = 0.12）。主要疗效分析中组间无显着差异，后验概率为0.51（贝叶斯处理差异：-0.03） mm Hg [95% CI: -2.82 至 2.77 mm Hg])。然而，假手术对照组患者的药物强度发生了变化和增加。与 6 个月时假手术对照组相比，RDN 与诊室收缩压降低相关（调整后治疗差异：-4.9 mm Hg；P = 0.0015）。夜间血压降低和获胜比分析也有利于 RDN。253 名接受评估的患者中发生了 1 起不良安全事件。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：主要分析中各组之间没有显着差异。然而，多个次要终点分析有利于 RDN 优于假手术对照。（SPYRAL HTN-ON MED 研究 [使用 Symplicity Spyral 多电极肾去神经系统进行肾去神经的全球临床研究在没有抗高血压药物的情况下高血压不受控制的患者中]；NCT02439775）。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37914510/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37914510</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.045>10.1016/j.jacc.2023.08.045</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37914510</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>大卫·E·坎扎里</dc:creator><dc:creator>雷蒙德·R·汤森</dc:creator><dc:creator>加尾一臣</dc:creator><dc:creator>菲利克斯·马哈福德</dc:creator><dc:creator>迈克尔·韦伯</dc:creator><dc:creator>罗兰·E·施密德</dc:creator><dc:creator>斯图尔特·波科克</dc:creator><dc:creator>康斯坦丁诺斯·齐乌菲斯</dc:creator><dc:creator>迪米特里奥斯·康斯坦丁尼迪斯</dc:creator><dc:creator>詹姆斯·崔</dc:creator><dc:creator>卡拉·东</dc:creator><dc:creator>卢卡斯·兰黛</dc:creator><dc:creator>黛比·L·科恩</dc:creator><dc:creator>小林大成</dc:creator><dc:creator>阿克塞尔·施密德</dc:creator><dc:creator>大卫·P·李</dc:creator><dc:creator>马德良</dc:creator><dc:creator>约阿希姆·韦尔</dc:creator><dc:creator>托尔加·阿格迪尔利奥卢</dc:creator><dc:creator>马库斯·P·施莱奇</dc:creator><dc:creator>沙拉德·谢蒂</dc:creator><dc:creator>钱丹·M·德维雷迪</dc:creator><dc:creator>珍妮丝·李</dc:creator><dc:creator>青木二郎</dc:creator><dc:creator>安德鲁·SP·夏普</dc:creator><dc:creator>理查德·安德森</dc:creator><dc:creator>马丁·费伊</dc:creator><dc:creator>凡妮莎·德布鲁因</dc:creator><dc:creator>桑迪普·布拉尔</dc:creator><dc:creator>迈克尔·伯姆</dc:creator><dc:creator>SPYRAL HTN-ON MED 研究人员</dc:creator><dc:date>2023-11-01</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>服用抗高血压药物的患者去肾神经术的安全性和有效性</dc:title><dc:identifier>下午：37914510</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.045</dc:identifier></item><item><title>磁性软机器人在体外操纵细胞外基质</title><link/>https://pubmed.ncbi.nlm.nih.gov/37913767/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>动态机械控制对细胞微环境的重要性早已得到人们的重视。在最近一期的《Device》杂志中，Raman 及其同事设计了一种巧妙但可推广的工具来实现这一目标，并说明了工程细胞外基质的磁刺激可诱导肌肉纤维按照程序排列发挥作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 10 月 24 日：S0092-8674(23)01127-3. doi: 10.1016/j.cell.2023.10.011. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">动态机械控制对细胞微环境的重要性早已得到人们的重视。在最近一期的《Device》杂志中，Raman 及其同事设计了一种巧妙但可推广的工具来实现这一目标，并说明了工程细胞外基质的磁刺激可诱导肌肉纤维按照程序排列发挥作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37913767/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37913767</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.10.011>10.1016/j.cell.2023.10.011</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37913767</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator>阿维纳瓦·罗伊</dc:creator><dc:creator>克劳迪娅·勒贝尔</dc:creator><dc:date>2023-11-01</dc:date><dc:source>细胞</dc:source><dc:title>磁性软机器人在体外操纵细胞外基质</dc:title><dc:identifier>下午：37913767</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.10.011</dc:identifier></item><item><title>教育程度与心血管疾病的终生风险</title><link/>https://pubmed.ncbi.nlm.nih.gov/37910110/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231103021054&amp;v=2.17.9.post6+86293ac<description>结论和相关性：较低的教育程度与成年期的终生心血管疾病风险相关；高等教育转化为健康长寿。教育政策举措可能与长期健康益处相关。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 年 11 月 1 日。doi：10.1001/jamacardio.2023.3990。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">重要性：教育是健康的社会决定因素。量化其与终生心血管疾病 (CVD) 风险的关系具有公共卫生重要性。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">目的：计算 CVD 事件和 CVD 亚型的终生风险估计，并通过教育估计有和没有 CVD 的生存年数。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">设计、环境和参与者：包括以社区为基础的队列研究，其中使用了 1985 年至 2015 年 6 项前瞻性队列研究的个人数据汇总，并裁定了心血管事件。研究小组使用改良的 Kaplan-Meier 评估了教育与终生 CVD 风险之间的关联和 Cox 模型解释了非心血管死亡的竞争风险。研究小组通过欧文限制均值的教育以及在 CVD 风险评估中增加教育程度的效用估计了有和没有 CVD 的生存年数。参与者（基线 40 至 59 岁和 60 岁）年龄到 79 岁）基线时没有 CVD，并且有完整的教育、心血管危险因素和前瞻性 CVD 结果数据。数据分析时间为 2022 年 1 月至 2022 年 9 月。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">暴露：教育程度（高中以下、高中毕业、部分大学或大学毕业生）。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOME AND MEASURES: Cardiovascular events (fatal and nonfatal coronary heart disease, heart failure, and stroke; CVD-related deaths; and total CVD encompassing any of these events). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: There were 40 998 participants (23 305 female [56.2%]) with a mean (SD) age of 58.1 (9.7) years for males and 58.3 (9.9) years for females. Compared with college graduates, those with less than high school or high school completion had higher lifetime CVD risks. Among middle-aged men, the competing hazard ratios (HRs) for a CVD event were 1.58 (95% CI, 1.38-1.80), 1.30 (95% CI, 1.10-1.46), and 1.16 (95% CI, 1.00-1.34) in those with less than high school, high school, and some college, respectively, compared with those with college completion. Among women, these competing HRs were 1.70 (95% CI, 1.49-1.95), 1.19 (95% CI, 1.05-1.35), and 0.98 (95% CI, 0.83-1.15). Individuals with higher education had longer duration of life prior to incident CVD. Education provided limited contribution toward enhancing CVD risk prediction. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS AND RELEVANCE: Lower education was associated with lifetime CVD risk across adulthood; higher education translated to healthy longevity. Educational policy initiatives may associate with long-term health benefits.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37910110/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37910110</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3990>10.1001/jamacardio.2023.3990</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37910110</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator> Jared W Magnani</dc:creator><dc:creator> Hongyan Ning</dc:creator><dc:creator> John T Wilkins</dc:creator><dc:creator> Donald M Lloyd-Jones</dc:creator><dc:creator> Norrina B Allen</dc:creator><dc:date> 2023-11-01</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Educational Attainment and Lifetime Risk of Cardiovascular Disease</dc:title><dc:identifier> pmid:37910110</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3990</dc:identifier></item><item><title> Clinical Outcomes by Sex After Pulsed Field Ablation of Atrial Fibrillation</title><link/> https://pubmed.ncbi.nlm.nih.gov/37910101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231103021054&amp;v=2.17.9.post6+86293ac<description> CONCLUSION AND RELEVANCE: Results of this cohort study suggest that after PFA for AF, there were no significant sex differences in clinical effectiveness or safety events. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Nov 1. doi: 10.1001/jamacardio.2023.3752. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> IMPORTANCE: Previous studies evaluating the association of patient sex with clinical outcomes using conventional thermal ablative modalities for atrial fibrillation (AF) such as radiofrequency or cryoablation are controversial due to mixed results. Pulsed field ablation (PFA) is a novel AF ablation energy modality that has demonstrated preferential myocardial tissue ablation with a unique safety profile. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: To compare sex differences in patients undergoing PFA for AF in the Multinational Survey on the Methods, Efficacy, and Safety on the Postapproval Clinical Use of Pulsed Field Ablation (MANIFEST-PF) registry. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study of MANIFEST-PF registry data, which included consecutive patients undergoing postregulatory approval treatment with PFA to treat AF between March 2021 and May 2022 with a median follow-up of 1 year. MANIFEST-PF is a multinational, retrospectively analyzed, prospectively enrolled patient-level registry including 24 European centers. The study included all consecutive registry patients (age ≥18 years) who underwent first-ever PFA for paroxysmal or persistent AF. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> EXPOSURE: PFA was performed on patients with AF. All patients underwent pulmonary vein isolation and additional ablation, which was performed at the discretion of the operator. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MAIN OUTCOMES AND MEASURES: The primary effectiveness outcome was freedom from clinically documented atrial arrhythmia for 30 seconds or longer after a 3-month blanking period. The primary safety outcome was the composite of acute (&lt;7 days postprocedure) and chronic (>;7 days) major adverse events (MAEs). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Of 1568 patients (mean [SD] age, 64.5 [11.5] years; 1015 male [64.7%]) with AF who underwent PFA, female patients, as compared with male patients, were older (mean [SD] age, 68 [10] years vs 62 [12] years; P &lt; .001), had more paroxysmal AF (70.2% [388 of 553] vs 62.4% [633 of 1015]; P = .002) but had fewer comorbidities such as coronary disease (9% [38 of 553] vs 15.9% [129 of 1015]; P &lt; .001), heart failure (10.5% [58 of 553] vs 16.6% [168 of 1015]; P = .001), and sleep apnea (4.7% [18 of 553] vs 11.7% [84 of 1015]; P &lt; .001). Pulmonary vein isolation was performed in 99.8% of female (552 of 553) and 98.9% of male (1004 of 1015; P = .90) patients. Additional ablation was performed in 22.4% of female (124 of 553) and 23.1% of male (235 of 1015; P = .79) patients. The 1-year Kaplan-Meier estimate for freedom from atrial arrhythmia was similar in male and female patients (79.0%; 95% CI, 76.3%-81.5% vs 76.3%; 95% CI, 72.5%-79.8%; P = .28). There was also no significant difference in acute major AEs between groups (male, 1.5% [16 of 1015] vs female, 2.5% [14 of 553]; P = .19). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSION AND RELEVANCE: Results of this cohort study suggest that after PFA for AF, there were no significant sex differences in clinical effectiveness or safety events.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37910101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37910101</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.3752>10.1001/jamacardio.2023.3752</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37910101</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator> Mohit K Turagam</dc:creator><dc:creator> Petr Neuzil</dc:creator><dc:creator> Boris Schmidt</dc:creator><dc:creator> Tobias Reichlin</dc:creator><dc:creator> Kars Neven</dc:creator><dc:creator> Andreas Metzner</dc:creator><dc:creator> Jim Hansen</dc:creator><dc:creator> Yuri Blaauw</dc:creator><dc:creator> Philippe Maury</dc:creator><dc:creator> Thomas Arentz</dc:creator><dc:creator> Philipp Sommer</dc:creator><dc:creator> Ante Anic</dc:creator><dc:creator> Frederic Anselme</dc:creator><dc:creator> Serge Boveda</dc:creator><dc:creator> Tom Deneke</dc:creator><dc:creator> Stephan Willems</dc:creator><dc:creator> Pepijn van der Voort</dc:creator><dc:creator> Roland Tilz</dc:creator><dc:creator> Moritoshi Funasako</dc:creator><dc:creator> Daniel Scherr</dc:creator><dc:creator> Reza Wakili</dc:creator><dc:creator> Daniel Steven</dc:creator><dc:creator> Josef Kautzner</dc:creator><dc:creator> Johan Vijgen</dc:creator><dc:creator> Pierre Jais</dc:creator><dc:creator> Jan Petru</dc:creator><dc:creator> Julian Chun</dc:creator><dc:creator> Laurent Roten</dc:creator><dc:creator> Anna Füting</dc:creator><dc:creator> Marc D Lemoine</dc:creator><dc:creator> Martin Ruwald</dc:creator><dc:creator> Bart A Mulder</dc:creator><dc:creator> Anne Rollin</dc:creator><dc:creator> Heiko Lehrmann</dc:creator><dc:creator> Thomas Fink</dc:creator><dc:creator> Zrinka Jurisic</dc:creator><dc:creator> Corentin Chaumont</dc:creator><dc:creator> Raquel Adelino</dc:creator><dc:creator> Karin Nentwich</dc:creator><dc:creator> Melanie Gunawardene</dc:creator><dc:creator> Alexandre Ouss</dc:creator><dc:creator> Christian-Hendrik Heeger</dc:creator><dc:creator> Martin Manninger</dc:creator><dc:creator> Jan-Eric Bohnen</dc:creator><dc:creator> Arian Sultan</dc:creator><dc:creator> Petr Peichl</dc:creator><dc:creator> Pieter Koopman</dc:creator><dc:creator> Nicolas Derval</dc:creator><dc:creator> Thomas Kueffer</dc:creator><dc:creator> Vivek Y Reddy</dc:creator><dc:date> 2023-11-01</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Clinical Outcomes by Sex After Pulsed Field Ablation of Atrial Fibrillation</dc:title><dc:identifier> pmid:37910101</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.3752</dc:identifier></item><item><title> Pulsed Field Closes Gender Gap in Atrial Fibrillation Ablation-Electrifying Insights</title><link/> https://pubmed.ncbi.nlm.nih.gov/37910095/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231103021054&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> JAMA Cardiol. 2023 Nov 1. doi: 10.1001/jamacardio.2023.4009. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37910095/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231103021054&v=2.17.9.post6+86293ac">37910095</a> | DOI: <a href=https://doi.org/10.1001/jamacardio.2023.4009>10.1001/jamacardio.2023.4009</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37910095</guid><pubDate> Wed, 01 Nov 2023 06:00:00 -0400</pubDate><dc:creator> Peter M Kistler</dc:creator><dc:creator> Louise Segan</dc:creator><dc:date> 2023-11-01</dc:date><dc:source> JAMA cardiology</dc:source><dc:title> Pulsed Field Closes Gender Gap in Atrial Fibrillation Ablation-Electrifying Insights</dc:title><dc:identifier> pmid:37910095</dc:identifier><dc:identifier> doi:10.1001/jamacardio.2023.4009</dc:identifier></item></channel></rss>